Arvinas Earnings Call: VEPPANU Win, Pipeline Momentum

Arvinas Holding Company ((ARVN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Arvinas Holding’s latest earnings call painted a broadly upbeat picture, anchored by a landmark U.S. approval and deeper pipeline progress that overshadowed softer financials. Management stressed that the first-ever heterobifunctional PROTAC approval, strengthened partnerships, and disciplined cost controls leave the company better positioned despite revenue volatility and competitive risks.

VEPPANU Approval Validates PROTAC Platform

The FDA’s approval of VEPPANU for ESR1‑mutant ER+/HER2‑ advanced breast cancer marks the first heterobifunctional PROTAC degrader to reach the market, a major scientific and strategic milestone. Executives framed this as strong validation of Arvinas’s targeted protein degradation platform, arguing it de‑risks the modality and supports confidence in the broader pipeline.

Rigel Deal Creates New Commercial Path and Economics

Arvinas and Pfizer signed a global licensing deal with Rigel, handing Rigel commercialization, development, and manufacturing duties for VEPPANU. The partners will share economics 50/50 on the out‑license, with Arvinas flagging upfront and near‑term milestones plus an expected approval milestone later this year as a meaningful new source of cash.

Cash Runway Extends Into Late Decade

The company closed Q1 2026 with $614.9 million in cash, cash equivalents, and marketable securities, down from $685.4 million at year‑end but still described as ample. Management reiterated that this balance should fund operations into the second half of 2028, covering four ongoing Phase 1 trials and key data readouts without needing near‑term capital raises.

Cost Discipline Resets Expense Base

Non‑GAAP R&D and G&A expenses fell sharply year over year, dropping by $25.0 million and $10.1 million, respectively, as Arvinas completed major cost reduction initiatives. Total non‑GAAP expenses declined to $67.3 million, a $35.1 million cut that management said reflects a new 2026 cost structure designed to stretch the existing cash runway and sharpen portfolio focus.

ARV‑102 Shows Biomarker Hit and Tolerability

In early Parkinson’s disease testing, ARV‑102 drove approximately 50% or greater reductions in CSF LRRK2 by day 14, sustained through day 28, alongside dose‑dependent changes in downstream markers like CD68 and GPNMB. The drug was generally well tolerated with no serious adverse events through 28 days, supporting continued development as a potential first‑in‑class LRRK2 degrader.

ARV‑806 Delivers Potent Preclinical KRAS Activity

ARV‑806, targeting KRAS G12D, showed roughly 25–40‑fold greater preclinical potency versus current clinical‑stage KRAS G12D agents, with more than 90% degradation sustained for seven days after a single dose. Phase 1 dose escalation enrollment finished ahead of schedule, and the company plans to share initial clinical data later this year, positioning ARV‑806 as a key oncology catalyst.

ARV‑393 Advances With Early Responses and Combos

For ARV‑393, a BCL6 degrader, Arvinas reported early clinical responses in relapsed or refractory B‑ and T‑cell lymphomas, even at exposures below predicted efficacious levels, alongside robust BCL6 degradation. A combination study with glofitamab in diffuse large B‑cell lymphoma has begun, reflecting a strategy to embed the asset in emerging immuno‑oncology regimens.

Pipeline Breadth From Discovery to Clinic

Management highlighted four ongoing Phase 1 programs and more than 2,000 patients or volunteers previously dosed across the platform as evidence of translational strength. New entrants, including ARV‑6723 (an HPK1 immuno‑oncology degrader) and an oral pan‑KRAS program, are slated to move into the clinic later this year, underscoring the breadth of Arvinas’s discovery engine.

Revenue and Cash Declines Cloud Near-Term Financials

Q1 2026 revenue plunged to $15.6 million from $188.8 million a year earlier, a roughly 92% drop largely tied to lower recognition from the vepdegestrant collaboration after changes in estimated program costs. Cash also declined by $70.5 million versus year‑end, reflecting ongoing burn and smaller upfront or collaboration receipts, though management emphasized the long runway remains intact.

Regulatory Hold and Spending Cuts Pose Risks

The FDA placed the planned U.S. Phase 1b ARV‑102 study in PSP on hold pending chronic nonhuman primate toxicology data expected mid‑2026, delaying domestic patient dosing even as European trials continue. Management also acknowledged that lower R&D and G&A outlays, while boosting efficiency, could limit the pace of some programs as the company balances ambition with fiscal discipline.

Competitive and Commercial Uncertainties Around KRAS and VEPPANU

Arvinas flagged a crowded and fast‑moving KRAS and RAS landscape, where safety concerns and aggressive competitors raise execution risk for ARV‑806 and the pan‑KRAS program despite strong preclinical data. The company also noted that Rigel holds global VEPPANU rights and will need partners outside the U.S., leaving timing and magnitude of international economics uncertain for now.

Guidance Underscores Long Runway and Key 2026 Catalysts

Looking ahead, Arvinas reaffirmed guidance that its $614.9 million cash pile should fund operations into the second half of 2028 while supporting four Phase 1 programs and new entrants like ARV‑6723. Management pointed to ARV‑102’s U.S. Phase 1b start by late 2026 (pending mid‑2026 tox data), clinical updates on ARV‑806 and ARV‑393 later this year, and expected VEPPANU‑related milestones and Rigel payments as key operational and financial catalysts.

Arvinas’s earnings call ultimately balanced near‑term financial softness and regulatory noise against landmark scientific wins and a more sustainable cost base. With VEPPANU’s approval validating its platform, a deepening early‑stage pipeline, and a cash runway stretching into 2028, the company is positioning itself as a long‑duration story for investors willing to navigate competitive and regulatory risks.